Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 14;39(3):207-211.
doi: 10.3760/cma.j.issn.0253-2727.2018.03.007.

[Impact on platelet recovery of recombinant human thrombopoietin in severe aplastic anemia patients with allogeneic hematopoietic stem cell transplantation]

[Article in Chinese]
Y Song  1 , F Zhou, N X Song, X M Liu, Z Yu, L N Xie, X C Song, X Li
Affiliations

[Impact on platelet recovery of recombinant human thrombopoietin in severe aplastic anemia patients with allogeneic hematopoietic stem cell transplantation]

[Article in Chinese]
Y Song et al. Zhonghua Xue Ye Xue Za Zhi. .

Abstract
in English, Chinese

Objective: To investigate and analyze the impact on PLT recovery of recombinant human thrombopoietin (rhTPO) in severe aplastic anemia (SAA) patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: A retrospective analysis of Hematology Division of General Hospital of Jinan Military Command was conducted in the 85 SAA cases who treated with allo-HSCT from January 2010 to March 2017. According to the administration of medicines for platelets, 85 patients were divided into rhTPO group (n=29), rhIL-11 group (n=27) and blank group (n=29), respectively. The median time of PLT ≥20×109/L, PLT ≥50×109/L, and PLT ≥100×109/L, the numbers of megakaryocytes in marrow smear (25±5) days after transplantation and the quantities of platelet transfusion were analyzed retrospectively. The adverse events of rhTPO and rhIL-11 groups were observed. Results: There were no significant differences in the recovery of granulocytes and PLT ≥20×109/L among the three groups (P>0.05). The time of PLT ≥50×109/L in rhTPO group was shorter than that in blank group [16.5 (11-39) d vs 22 (14-66) d, P<0.05], as well as the time of PLT ≥100×109/L [rhTPO: 23 (12-51) d; rhIL-11: 28 (12-80) d; blank group: 35 (18-86) d, P<0.05]. Platelet transfusions were also less in rhTPO group than in rhIL-11 and blank groups [20 (10-30) U, 30 (10-50) U, 35 (10-70) U, P<0.05]. The counts of megakaryocyte in rhTPO group, rhIL-11 group and blank group were 31.5 (0-200), 12 (0-142) and 11(0-187) (P<0.05), respectively. The difference between rhTPO group and rhIL-11 group was statistically significant (P<0.05), but no difference between rhIL-11 group and blank group (P>0.05). Multivariate analysis showed that rhTPO was an independent factor for platelet recovery [HR=4.01 (95%CI 1.81-9.97), P=0.010]. The rhTPO group had no obvious adverse events. Conclusion: rhTPO can promote platelet recovery of SAA patients after allo-HSCT, reduce platelet transfusion with safety.

目的： 分析重组人血小板生成素（rhTPO）促进重型再生障碍性贫血（SAA）患者异基因造血干细胞移植（allo-HSCT）后血小板恢复的疗效及安全性。 方法： 对2010年1月至2017年3月期间85例接受allo-HSCT治疗的SAA患者进行回顾性分析。根据移植后升血小板药物的使用情况，将85例患者分为rhTPO组（29例）、rhIL-11组（27例）和空白组（29例），比较三组PLT≥20×109/L、PLT≥50×109/L、PLT≥100×109/L的恢复时间以及移植后（25±5）d骨髓巨核细胞计数、移植期间血小板输注量，观察药物不良反应。 结果： rhTPO、rhIL-11、空白组粒细胞植入和PLT≥20×109/L的中位时间差异均无统计学意义（P>0.05）。rhTPO组PLT≥50×109/L时间短于空白组[16.5（11~39）d对22（14~66）d，P<0.05]；rhTPO组PLT≥100×109/L时间[23（12~51）d]短于rhIL-11组[28（12~80）d]及空白组[35（18~86）d]（P<0.05）。rhTPO组移植期间血小板输注量少于rhIL-11组及空白组[分别为20（10~30）、30（10~50）、35（10~70）U，P<0.05]。rhTPO、rhIL-11、空白组移植后（25±5）d骨髓巨核细胞中位计数分别为31.5（0~200）、12（0~142）、11（0~187）个，rhTPO组与rhIL-11组比较差异有统计学意义（P<0.05），rhIL-11组与空白组比较差异无统计学意义（P>0.05）。多因素分析显示，应用rhTPO是影响血小板恢复的独立影响因素[HR=4.01（95%CI 1.81~8.97），P=0.010]。rhTPO组未见明显不良反应。 结论： rhTPO可以促进SAA患者allo-HSCT后血小板恢复、减少血小板输注量，并且安全性较好。.

Keywords: Anemia, aplastic; Hematopoietic stem cell transplantation; Platelet transfusion; Thrombopoietin.

PubMed Disclaimer

Figures

图1
图1. 85例重型再生障碍性贫血患者异基因造血干细胞移植后生存曲线
图2
图2. rhTPO、rhIL-11及空白组重型再生障碍性贫血患者异基因造血干细胞移植后生存曲线
rhTPO：重组人血小板生成素；rhIL-11：重组人白细胞介素11
See this image and copyright information in PMC

References

    1. 中华医学会血液学分会红细胞疾病(贫血)学组. 再生障碍性贫血诊断与治疗中国专家共识(2017年版)[J] 中华血液学杂志. 2017;38(1):1–5. doi: 10.3760/cma.j.issn.0253-2727.2017.01.001. - DOI
    1. 苗 瞄, 吴 德沛, 曹 祥山, et al. 血小板生成素在异基因造血干细胞移植后促进血小板植入的临床研究[J] 中华血液学杂志. 2012;33(5):362–365. doi: 10.3760/cma.j.issn.0253-2727.2012.05.003. - DOI
    1. Han TT, Xu LP, Liu DH, et al. Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial[J] Ann Hematol. 2015;94(1):117–128. doi: 10.1007/s00277-014-2158-1. - DOI - PubMed
    1. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin[J] Nature. 1994;369(6481):568–571. doi: 10.1038/369568a0. - DOI - PubMed
    1. Pramono A, Zahabi A, Morishima T, et al. Thrombopoietin induces hematopoiesis from mouse ES cells via HIF-1α-dependent activation of a BMP4 autoregulatory loop[J] Ann N Y Acad Sci. 2016;1375(1):38–51. doi: 10.1111/nyas.13138. - DOI - PubMed